Assessing Atlassian (TEAM) Valuation After A Sharp Disconnect In Recent And 1-Year Share Returns

Advertisement

Recent share performance puts Atlassian (TEAM) under the microscope

Recent volatility in Atlassian (TEAM) has pushed the stock into focus, with a near 19% gain over the past month contrasting with a year to date decline of about 45% and a 1 year total return drop of roughly 60%.

See our latest analysis for Atlassian.

Atlassian’s recent 19.4% 30 day share price return and 16.7% 90 day share price return contrast sharply with its 59.5% 1 year total shareholder return decline, suggesting short term momentum is building while longer term holders remain significantly underwater.

If this kind of rebound has you thinking about where else growth and volatility might create openings, it could be worth scanning 63 profitable AI stocks that aren't just burning cash

With Atlassian reporting US$6,190.2m in revenue, a net loss of US$216.8m and trading at a sizeable discount to both analyst targets and some intrinsic estimates, is the stock on sale, or is the market already discounting future growth?

Most Popular Narrative: 58.3% Undervalued

According to the most followed narrative, Atlassian’s fair value of $204.74 sits well above the last close at $85.42, which puts a spotlight on how ambitious the long term assumptions really are.

Based on analyst consensus and industry trends, Atlassian’s revenue is expected to maintain a strong double-digit growth trajectory. Analysts forecast revenue growth around 15–20% annually in the coming years. In FY2024 Atlassian delivered $4.36B revenue (23% YoY) and is projected to reach ~$5.28B in FY2025. Consensus estimates see revenue around $7.6B by FY2027. Looking further to 2030, I assume Atlassian can grow revenue roughly in line with the mid-teens analyst forecast, with potential upside from the AI and enterprise catalysts. This yields an estimated revenue in the ~$11–12 billion range by 2030. Such growth is underpinned by Atlassian’s expanding addressable market and multiple growth levers (new products, cloud conversion, user expansion). It is worth noting Atlassian’s own long-term target: even after doubling in size, it would still be capturing under 20% of its identified market opportunity, leaving room for sustained growth beyond five years.

Read the complete narrative.

Curious how this valuation leans on fast improving margins, ambitious revenue compounding and a rich future earnings multiple. The full narrative lays out the exact growth, profitability and pricing assumptions that bridge today’s share price to that $204.74 figure.

Result: Fair Value of $204.74 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh up competitive pressure from larger software rivals, as well as the risk that enterprise adoption or cloud migrations take longer than this narrative assumes.

Find out about the key risks to this Atlassian narrative.

Next Steps

With such mixed signals across valuation, growth assumptions, risks and rewards, it makes sense to move quickly and review the underlying detail yourself, starting with the 4 key rewards and 1 important warning sign.

Ready for more investment ideas?

If Atlassian has your attention, do not stop here. Broaden your watchlist with a few focused screens that surface stocks matching different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:TEAM

Atlassian

Provides a collaboration software that enables organizations to connect all teams through a system of work that unlocks productivity at scale worldwide.

High growth potential with excellent balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0